These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38436190)

  • 1. Impact of muscle mass loss on outcomes in advanced or metastatic gastric cancer patients receiving a second-line treatment.
    Zurlo V; Rosa F; Rinninella E; Pontolillo L; Beccia V; Maratta M; Tortora G; Alfieri S; Pozzo C; Strippoli A
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(4):1575-1584. PubMed ID: 38436190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of sarcopenia with severe chemotherapy toxicities and survival in patients with advanced gastric cancer.
    Chan WL; Yun HB; Cheung EE; Liu M; Hou LY; Lam KO; Wong IY; Chiu WK; Law S; Kwong D
    Oncologist; 2024 Oct; 29(10):e1272-e1279. PubMed ID: 38885304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
    Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
    Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A
    J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
    Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
    BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Li S; Liu Z; Ren Y; Liu J; Lv S; He P; Yang Y; Sun Y; Chang J; Luo D; Cong M
    Front Nutr; 2022; 9():900823. PubMed ID: 35923193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer.
    Şahin MEH; Akbaş F; Yardimci AH; Şahin E
    BMC Cancer; 2023 Sep; 23(1):911. PubMed ID: 37770828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of surgery-induced sarcopenia in the survival of gastric cancer patients: a sex-specific analysis.
    Lee JK; Park YS; Lee K; Youn SI; Won Y; Min SH; Ahn SH; Park DJ; Kim HH
    J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):1897-1907. PubMed ID: 34533290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcopenia is Associated with Perioperative Outcomes in Gastric Cancer Patients Undergoing Gastrectomy.
    Shi B; Liu S; Chen J; Liu J; Luo Y; Long L; Lan Q; Zhang Y
    Ann Nutr Metab; 2019; 75(4):213-222. PubMed ID: 31846973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
    Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Effects of Low Preoperative Skeletal Muscle Mass in Patients Undergoing Gastrectomy for Gastric Cancer.
    Sakurai K; Kubo N; Tamura T; Toyokawa T; Amano R; Tanaka H; Muguruma K; Yashiro M; Maeda K; Hirakawa K; Ohira M
    Ann Surg Oncol; 2017 Sep; 24(9):2712-2719. PubMed ID: 28477088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
    Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
    Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of skeletal muscle mass in patients with recurrent gastric cancer.
    Matsunaga T; Satio H; Miyauchi W; Shishido Y; Miyatani K; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
    World J Surg Oncol; 2021 Jun; 19(1):170. PubMed ID: 34116681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer.
    Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG
    Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
    Miyamoto Y; Hiyoshi Y; Akiyama T; Kiyozumi Y; Eto K; Yohei N; Iwagami S; Baba Y; Yoshida N; Baba H
    Digestion; 2019; 99(1):79-85. PubMed ID: 30554226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strong impact of sarcopenia as a risk factor of survival in resected gastric cancer patients: first Italian report of a Bicentric study.
    Ricciardolo AA; De Ruvo N; Serra F; Prampolini F; Solaini L; Battisti S; Missori G; Fenocchi S; Rossi EG; Sorrentino L; Salati M; Spallanzani A; Cautero N; Pecchi A; Ercolani G; Gelmini R
    Updates Surg; 2022 Feb; 74(1):283-293. PubMed ID: 34699033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.
    Gallois C; Bourillon C; Auclin E; Artru P; Lièvre A; Lecomte T; Locher C; Marthey L; Faroux R; Pernot S; Barret M; Taieb J
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101603. PubMed ID: 33662782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer.
    Hayashi N; Ando Y; Gyawali B; Shimokata T; Maeda O; Fukaya M; Goto H; Nagino M; Kodera Y
    Oncol Rep; 2016 Mar; 35(3):1727-31. PubMed ID: 26648321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.